AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31398573 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed oxytocin (DO)
Number of subjects: 64
Study 31398573 — intervention group
Group type: COMPARATOR
Intervention: Immediate oxytocin (IO)
Number of subjects: 64
Study 29191231 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation analysis
Number of subjects: 0
Study 29191231 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting all participants' LTFU as non-users of contraception
Number of subjects: 0
Study 29191231 — intervention group
Group type: COMPARATOR
Intervention: Complete case analysis
Number of subjects: 0
Study 27927658 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (Hb ≤100 g/L)
Number of subjects: 0
Study 27927658 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (Hb ≤80 g/L)
Number of subjects: 0
Study 24438370 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene (BZA) 20 mg/Conjugated Estrogens (CE) 0.45 or 0.625 mg
Number of subjects: 1843
Study 24438370 — intervention group
Group type: COMPARATOR
Intervention: Conjugated Estrogens (CE) 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg
Number of subjects: 1843
Study 24438370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 1843
Study 24438370 — intervention group
Group type: COMPARATOR
Intervention: Bazedoxifene (BZA) 20 mg
Number of subjects: 1843
Study 22020758 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention (16 cognitive-behavioral, small-group sessions)
Number of subjects: 339
Study 22020758 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 339
Study 19729593 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP support 1:2
Number of subjects: 25
Study 19729593 — intervention group
Group type: EXPERIMENTAL
Intervention: IABP support 1:1
Number of subjects: 25
Study 17632131 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg trospium chloride once daily
Number of subjects: 601
Study 17632131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study 15334434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support groups
Number of subjects: 112
Study 15334434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual support groups (for those attending at least 5 of 10 sessions)
Number of subjects: 112
Study 11751144 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS 284756 (600 mg single dose)
Number of subjects: 8
Study 9526970 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg
Number of subjects: 60
Study 9526970 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg
Number of subjects: 60
Study 9526970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rIL‐2 (0.2 x 10(6), 0.7 x 10(6), or 2 x 10(6) units/m2 per day for 5 consecutive days)
Number of subjects: 16
Study 8011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rIL‐2
Number of subjects: 16
Study 8011237 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rIL‐2 (highest dose)
Number of subjects: 16
Study 2544152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin-DHE (LMWH-DHE)
Number of subjects: 191
Study 2544152 — intervention group
Group type: COMPARATOR
Intervention: Conventional heparin-DHE (heparin-DHE/A)
Number of subjects: 191
Study 1201808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHA) and lawsone (2-hydroxy-1,4-naphthoquinone)
Number of subjects: 5
Study 1201808 — intervention group
Group type: COMPARATOR
Intervention: Dihydroxyacetone (DHA) alone
Number of subjects: 5
Study 1201808 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHA)
Number of subjects: 5
Study 31431236 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training
Number of subjects: 65
Study 31431236 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised training
Number of subjects: 65
Study 31431236 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training and Supervised training
Number of subjects: 65
Study 31431236 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 65
Study 28736006 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA+EA
Number of subjects: 66
Study 28736006 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 66
Study 25938807 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine
Number of subjects: 240
Study 25938807 — intervention group
Group type: COMPARATOR
Intervention: Trichlormethiazide
Number of subjects: 240
Study 23918952 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 850 mg once daily (group B)
Number of subjects: 144
Study 23918952 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib 425 mg twice daily (group C)
Number of subjects: 144
Study 23918952 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 144
Study 22127969 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral cyclophosphamide (CYC)
Number of subjects: 42
Study 22127969 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 42
Study 22127969 — intervention group
Group type: EXPERIMENTAL
Intervention: CYC cumulative dose
Number of subjects: 42
Study 19388967 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking and family history of diabetes
Number of subjects: 3164
Study 19388967 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity
Number of subjects: 3164
Study 19388967 — intervention group
Group type: EXPERIMENTAL
Intervention: Large waist circumference
Number of subjects: 3164
Study 19388967 — intervention group
Group type: EXPERIMENTAL
Intervention: High body mass index (BMI)
Number of subjects: 3164
Study 19388967 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and waist circumference
Number of subjects: 3164
Study 19388967 — intervention group
Group type: EXPERIMENTAL
Intervention: Short height
Number of subjects: 3164
Study 19388967 — intervention group
Group type: EXPERIMENTAL
Intervention: Short height and low hip circumference
Number of subjects: 3164
Study 16783073 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitix (antioxidants, superoxide dismutase, and catalase)
Number of subjects: 25
Study 15139572 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity physical group training in water
Number of subjects: 43
Study 15139572 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity physical group training on land
Number of subjects: 43
Study 15139572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 9588607 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage ingestion (4 mL x kg(‐1) every 15 min during exercise)
Number of subjects: 10
Study 9588607 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage ingestion (C)
Number of subjects: 10
Study 9588607 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage ingestion (P)
Number of subjects: 10
Study 7974686 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg)
Number of subjects: 400
Study 7974686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 2642616 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 20
Study 2642616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 985152 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant nitrosourea chemotherapy (carmustine, lomustine, or semustine)
Number of subjects: 62
Study 985152 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 62
Study 30419232 — intervention group
Group type: EXPERIMENTAL
Intervention: Competitive volleyball exercise (n=16)
Number of subjects: 48
Study 30419232 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompetitive volleyball exercise (n=16)
Number of subjects: 48
Study 30419232 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16)
Number of subjects: 48
Study 28032910 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus co-administration with octreotide LAR
Number of subjects: 182
Study 26048580 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30-270mg/d)
Number of subjects: 56
Study 26048580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 23383686 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise with super-imposed whole-body vibrations
Number of subjects: 0
Study 23383686 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise without super-imposed whole-body vibrations
Number of subjects: 0
Study 23383686 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Resistance exercise with and without WBV)
Number of subjects: 0
Study 22453228 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 20
Study 22453228 — intervention group
Group type: COMPARATOR
Intervention: Behavioral therapy
Number of subjects: 20
Study 18785848 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power He-Ne laser (output power 0.2 mW) for 10 min, applied eight times in the first 3-month period after non-surgical mechanical periodontal treatment.
Number of subjects: 16
Study 18785848 — intervention group
Group type: COMPARATOR
Intervention: Control sites received no additional treatment after non-surgical mechanical periodontal treatment.
Number of subjects: 16
Study 17475006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate care at a community hospital (n=72)
Number of subjects: 142
Study 17475006 — intervention group
Group type: COMPARATOR
Intervention: General hospital care (n=70)
Number of subjects: 142
Study 15804807 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 20
Study 15804807 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study 11266030 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program for diabetic nephropathy (urine samples collected from all patients)
Number of subjects: 247
Study 9034838 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 30
Study 9034838 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.0015% twice daily
Number of subjects: 30
Study 9034838 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily
Number of subjects: 30
Study 8302442 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of Nicardipine retard twice a day (b.i.d.) for 8 weeks
Number of subjects: 36
Study 8302442 — intervention group
Group type: COMPARATOR
Intervention: Captopril in a dose of 25 mg (b.i.d.) for 8 weeks
Number of subjects: 36
Study 2957900 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective coronary injection of echocontrast medium through the central lumen of the angioplasty catheter before balloon inflation (group A)
Number of subjects: 14
Study 2957900 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocontrast medium injected through the introducer catheter positioned in the left main coronary artery during balloon inflation (group B)
Number of subjects: 14
Study 2957900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary echocontrast injections (both groups)
Number of subjects: 14
Study 29298277 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP)
Number of subjects: 41
Study 29298277 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 41
Study 26397376 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for four days
Number of subjects: 336
Study 26397376 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics until two days after clinical symptom resolution
Number of subjects: 336
Study 25133794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg once daily for 1 year
Number of subjects: 110
Study 25133794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 21956447 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (260 μg/kg p.o.)
Number of subjects: 16
Study 21956447 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (260 μg/kg p.o.) + Ketanserin (40 mg p.o.)
Number of subjects: 16
Study 21956447 — intervention group
Group type: COMPARATOR
Intervention: Ketanserin (40 mg p.o.)
Number of subjects: 16
Study 21956447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20159701 — intervention group
Group type: COMPARATOR
Intervention: Postoperative general anesthesia and intravenous analgesia (group A)
Number of subjects: 60
Study 20159701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative general anesthesia combined with thoracic epidural anesthesia with postoperative epidural analgesia (group B)
Number of subjects: 60
Study 19123322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangyikang (TYK) combined with insulin therapy
Number of subjects: 74
Study 19123322 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy alone (Control)
Number of subjects: 74
Study 15850470 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha-2a 180 microg/week + RBV 1000 or 1200 mg/day + AMA 200 mg/day
Number of subjects: 362
Study 15850470 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha-2a 3 MU tiw + RBV 1000 or 1200 mg/day + AMA 200 mg/day
Number of subjects: 362
Study 15850470 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha-2a 3 MU tiw + RBV 1000 or 1200 mg/day
Number of subjects: 362
Study 15850470 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alpha-2a + RBV + AMA
Number of subjects: 362
Study 15850470 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha-2a + RBV + AMA
Number of subjects: 362
Study 15850470 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha-2a + RBV
Number of subjects: 362
Study 12861852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg total dose)
Number of subjects: 28
Study 12861852 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib
Number of subjects: 28
Study 12861852 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (paracetamol)
Number of subjects: 28
Study 12861852 — intervention group
Group type: COMPARATOR
Intervention: Nimesulide
Number of subjects: 28
Study 10577848 — intervention group
Group type: COMPARATOR
Intervention: One cycle of high-dose cytarabine
Number of subjects: 50
Study 10577848 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more cycles of high-dose cytarabine
Number of subjects: 50
Study 8733038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10‐20 mg once daily)
Number of subjects: 335
Study 8733038 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20‐40 mg twice daily)
Number of subjects: 335
Study 8733038 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 335
Study 8733038 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 335
Study 8733038 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril and Nifedipine
Number of subjects: 335
Study 1289173 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extracts (acid‐protected microtablets; Panzytrat ‐20,000; 5 x 2 capsules/day; proteases/capsule 1,000 Pharmacopoea europaea units) for 14 days followed by placebo for another 14 days.
Number of subjects: 47
Study 1289173 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days followed by pancreatic extracts for another 14 days.
Number of subjects: 47
Study 6146033 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g sucrose taken at the end of a mixed meal (meal B)
Number of subjects: 18
Study 6146033 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric amounts of starch (meal A)
Number of subjects: 18
Study 31426685 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA+TEA
Number of subjects: 40
Study 31426685 — intervention group
Group type: COMPARATOR
Intervention: TIVA
Number of subjects: 40
Study 29323577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (COC) - 1.5 mg estradiol and 2.5 mg nomegestrolacetate
Number of subjects: 202
Study 29323577 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk use of alcohol with COC
Number of subjects: 202
Study 29323577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 27825415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DEX 1 μg/kg (Group D1)
Number of subjects: 41
Study 27825415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal DEX 2 μg/kg (Group D2)
Number of subjects: 41
Study 26093980 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV short
Number of subjects: 1000
Study 26093980 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV standard
Number of subjects: 1000
Study 26093980 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 short
Number of subjects: 1000
Study 26093980 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV1 standard
Number of subjects: 1000
Study 26093980 — intervention group
Group type: EXPERIMENTAL
Intervention: tOPV standard
Number of subjects: 1000
Study 23589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused green tea (0.75% w/v, 180 mg total C)
Number of subjects: 0
Study 23589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused green tea (1.25% w/v)
Number of subjects: 0
Study 23589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused green tea (1.75% w/v)
Number of subjects: 0
Study 23589502 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused green tea (medium and high doses)
Number of subjects: 0
Study 20841435 — intervention group
Group type: EXPERIMENTAL
Intervention: Norm group comparison
Number of subjects: 0
Study 20841435 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 0
Study 20841435 — intervention group
Group type: EXPERIMENTAL
Intervention: Norm group
Number of subjects: 0
Study 17676393 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg q.d.) plus celecoxib (200 mg q.d.)
Number of subjects: 0
Study 17676393 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg q.d.) plus naproxen (500 mg b.i.d.)
Number of subjects: 0
Study 17676393 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (81 mg q.d.) plus placebo
Number of subjects: 0
Study 16115324 — intervention group
Group type: EXPERIMENTAL
Intervention: New oscillometric device for measuring pulse wave velocity
Number of subjects: 44
Study 12538214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sameridine (25 mg)
Number of subjects: 24
Study 12538214 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (15 mg)
Number of subjects: 24
Study 10650110 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution CT (HRCT)
Number of subjects: 30
Study 10650110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cine MR
Number of subjects: 30
Study 8712322 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.1 mg.kg‐1
Number of subjects: 120
Study 8712322 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.25 mg.kg‐1
Number of subjects: 120
Study 8712322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 1505606 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 40 mg every 8 h
Number of subjects: 12
Study 1505606 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 80 mg every 8 h
Number of subjects: 12
Study 1505606 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 120 mg every 8 h
Number of subjects: 12
Study 1505606 — intervention group
Group type: COMPARATOR
Intervention: theophylline alone (phase I)
Number of subjects: 12
Study 6832463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin three times a day (75 mg to 225 mg per day)
Number of subjects: 30
Study 6832463 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin as a single night-time dose (75 mg to 225 mg per day)
Number of subjects: 30
Study 6832463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dothiepin three times a day
Number of subjects: 30
Study 6832463 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin as a single night-time dose
Number of subjects: 30
Study 31016471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal interpersonal sensitivity dimensions
Number of subjects: 812
Study 31016471 — intervention group
Group type: COMPARATOR
Intervention: Control for depression symptoms
Number of subjects: 812
Study 28958422 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration reducing gloves (VR gloves)
Number of subjects: 12
Study 28958422 — intervention group
Group type: COMPARATOR
Intervention: Leather glove
Number of subjects: 12
Study 27842191 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab (Lucentis) in the sustained group
Number of subjects: 30
Study 27842191 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab (Lucentis) in the PRN group
Number of subjects: 30
Study 27842191 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with 0.3 mg ranibizumab (Lucentis)
Number of subjects: 30
Study 27842191 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab (Lucentis) overall
Number of subjects: 30
Study 25077364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 60
Study 25077364 — intervention group
Group type: COMPARATOR
Intervention: Ischemia-reperfusion
Number of subjects: 60
Study 25077364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 60
Study 25077364 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus ischemia-reperfusion
Number of subjects: 60
Study 25077364 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning plus ischemia-reperfusion
Number of subjects: 60
Study 22989543 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer auditing of mammographic screenings
Number of subjects: 311193
Study 22989543 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional films
Number of subjects: 311193
Study 22989543 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser‐printed films
Number of subjects: 311193
Study 22989543 — intervention group
Group type: COMPARATOR
Intervention: Control group (186 true negatives)
Number of subjects: 311193
Study 22989543 — intervention group
Group type: EXPERIMENTAL
Intervention: False negative traditional films
Number of subjects: 311193